Cargando…
Incidence and Risk of QTc Interval Prolongation among Cancer Patients Treated with Vandetanib: A Systematic Review and Meta-analysis
BACKGROUND: Vandetanib is a multikinase inhibitor that is under assessment for the treatment of various cancers. QTc interval prolongation is one of the major adverse effects of this drug, but the reported incidence varies substantially among clinical trials. We performed a systematic review and met...
Autores principales: | Zang, Jiajie, Wu, Shunquan, Tang, Lei, Xu, Xudong, Bai, Jie, Ding, Caicui, Chang, Yue, Yue, Long, Kang, Enming, He, Jia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3281826/ https://www.ncbi.nlm.nih.gov/pubmed/22363427 http://dx.doi.org/10.1371/journal.pone.0030353 |
Ejemplares similares
-
Ketamine-induced QTc interval prolongation
por: Singh, Tejinder S. Swaran, et al.
Publicado: (2017) -
Ticagrelor-Induced Prolongation of the QTc Interval
por: Ray, Avik, et al.
Publicado: (2019) -
Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors
por: Kloth, J S L, et al.
Publicado: (2015) -
Problems with Bazett QTc correction in paediatric screening of prolonged QTc interval
por: Andršová, Irena, et al.
Publicado: (2020) -
The risk of QTc-interval prolongation in COVID-19 patients treated with chloroquine
por: Sinkeler, F. S., et al.
Publicado: (2020)